Lestaurtinib

Lestaurtinib (rINN, codenamed CEP-701) is a tyrosine kinase inhibitor structurally related to staurosporine, and is being developed by Cephalon.

It is an inhibitor of FLT3, JAK2, TrkA, TrkB and TrkC.

Uses
It is undergoing research for the treatment of acute myelogenous leukemia (AML) and myeloproliferative disorders.

, it is in Phase II clinical trials for AML and Phase II clinical trials for myeloproliferative disorders.